Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294952 | 0.90 | NPSR1 (0.62) | NPSR1MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL25230837 | 0.88 | NPSR1 (0.60) | NPSR1MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7095263 | 0.88 | MEN1 (0.66) | NPSR1MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7753723 | 0.85 | NPSR1 (0.61) | NPSR1MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL25272620 | 0.85 | HDAC6 (0.62) | NPSR1MEN1KMT2AALDH1A1GAA | |
| SCHEMBL5838386 | 0.84 | RAB9A (0.55) | NPSR1MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL25277617 | 0.84 | HDAC6 (0.57) | NPSR1MEN1KMT2AALDH1A1CA12 | |
| SCHEMBL25272478 | 0.83 | ICMT (0.59) | NPSR1MEN1KMT2AALDH1A1CA12 | |
| SCHEMBL9480181 | 0.81 | MAPT (0.62) | NPSR1MEN1KMT2AALDH1A1GAA | |
| SCHEMBL10596118 | 0.81 | ALDH1A1 (0.61) | NPSR1MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074780-B2 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2006-07-11 | — | — | US | disclosed |
| US-7053114-B2 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-6797725-B2 | SUCH AS 4-METHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLILDENEMETHYL)-1H-PYRROLE-2-CARBOXYLIC ACID FOR PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS; ANTICANCER AGENTS | SUGEN, INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6649616-B2 | For therapy and prophylaxis of cardiovascular disorders caused by ischaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-09 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | NPSR1 1673/4885MEN1 2279/4885KMT2A 2464/4885 |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | NPSR1 2503/4885MEN1 3621/4885KMT2A 1772/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | NPSR1 2503/4885MEN1 3621/4885KMT2A 1772/4885 |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | NPSR1 1673/4885MEN1 2279/4885KMT2A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.